<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418483</url>
  </required_header>
  <id_info>
    <org_study_id>050003</org_study_id>
    <nct_id>NCT00418483</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion</brief_title>
  <acronym>PRIORITY</acronym>
  <official_title>A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of increasing doses of intra-thrombus
      Plasmin (Human) in acute peripheral arterial occlusion (aPAO). The ability of these Plasmin
      doses to dissolve the clots will be estimated by arteriography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an unmet need for proven thrombolytic agent in acute peripheral arterial occlusion
      (aPAO). The current assortment of plasminogen activators are slow to dissolve clots in the
      leg, and may lead to bleeding complications. Plasmin is a direct thrombolytic that may act
      more quickly when infused directly into the clot and thus assist in restoring blood flow to
      the leg. There is a large reserve in blood alpha-2 antiplasmin in the blood to rapidly
      inactivate Plasmin outside of the clot. Plasmin has the potential for an improved bleeding
      risk profile in aPAO.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombolysis</measure>
    <time_frame>Approximately 5 hours after start of treatment</time_frame>
    <description>Thrombolysis at the end of treatment compared to baseline by arteriography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis</measure>
    <time_frame>Approximately 2 hours after start of treatment</time_frame>
    <description>Thrombolysis at 120 minutes compared to baseline by arteriography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of open surgical procedures</measure>
    <time_frame>30 days</time_frame>
    <description>Percent of subjects at Day 30 who avoid open surgical procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of amputation</measure>
    <time_frame>30 days</time_frame>
    <description>Percent of subjects at Day 30 who avoid amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of additional catheter-directed thrombolysis with a plasminogen activator or mechanical device thrombectomy</measure>
    <time_frame>30 days</time_frame>
    <description>Percent of subjects at Day 30 who avoided additional catheter-directed thrombolysis with a plasminogen activator or mechanical device thrombectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of both open surgical procedures and additional thrombolysis with a plasminogen activator or mechanical device thrombectomy.</measure>
    <time_frame>30 days</time_frame>
    <description>Percent of subjects at Day 30 who avoided both open surgical procedures and additional thrombolysis with a plasminogen activator or mechanical device thrombectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic reperfusion defined as improvement in ankle brachial index (ABI)</measure>
    <time_frame>End of treatment, post intervention procedures, Day 1 to 2, Day 7, and Day 30</time_frame>
    <description>Physiologic reperfusion defined as improvement in ABI (increase of ≥ 0.15) determined at the end of treatment, post intervention procedures, Day 1 to 2, Day 7, and Day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency assessed by duplex ultrasound imaging</measure>
    <time_frame>Day 7 and Day 30</time_frame>
    <description>Patency assessed by duplex ultrasound imaging on the affected leg on Day 7 and Day 30</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <arm_group>
    <arm_group_label>Plasmin (Human) 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmin (Human) 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmin (Human) 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmin (Human ) 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmin (Human) 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmin (Human) 75 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmin (Human) 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmin (Human) 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmin (Human) 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmin (Human) 125 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmin (Human) 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmin (Human) 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmin (Human) 175 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasmin (Human) 175 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmin (Human) 25 mg</intervention_name>
    <description>Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.</description>
    <arm_group_label>Plasmin (Human) 25 mg</arm_group_label>
    <other_name>TAL-05-00018</other_name>
    <other_name>BAY-57-9602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmin (Human) 50 mg</intervention_name>
    <description>Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.</description>
    <arm_group_label>Plasmin (Human) 50 mg</arm_group_label>
    <other_name>TAL-05-00018</other_name>
    <other_name>BAY-57-9602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmin (Human) 75 mg</intervention_name>
    <description>Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.</description>
    <arm_group_label>Plasmin (Human) 75 mg</arm_group_label>
    <other_name>TAL-05-00018</other_name>
    <other_name>BAY-57-9602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmin (Human) 100 mg</intervention_name>
    <description>Plasmin (Human) 100 mg</description>
    <arm_group_label>Plasmin (Human) 100 mg</arm_group_label>
    <other_name>TAL-05-00018</other_name>
    <other_name>BAY-57-9602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmin (Human) 125 mg</intervention_name>
    <description>Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.</description>
    <arm_group_label>Plasmin (Human) 125 mg</arm_group_label>
    <other_name>TAL-05-00018</other_name>
    <other_name>BAY-57-9602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmin (Human) 150 mg</intervention_name>
    <description>Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.</description>
    <arm_group_label>Plasmin (Human) 150 mg</arm_group_label>
    <other_name>TAL-05-00018</other_name>
    <other_name>BAY-57-9602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmin (Human) 175 mg</intervention_name>
    <description>Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.</description>
    <arm_group_label>Plasmin (Human) 175 mg</arm_group_label>
    <other_name>TAL-05-00018</other_name>
    <other_name>BAY-57-9602</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Women of childbearing potential must use adequate contraception for the duration of
             the study and must have a negative pregnancy test prior to study entry.

          -  Unilateral limb ischemia: SVS acute ischemia Category I or IIa.

          -  Onset of symptoms &lt;/= 14 days.

          -  Thrombosed (non-embolic) infrainguinal graft (synthetic, autologous, or single outflow
             composite) or infrainguinal native artery. For native arteries, only occlusions of ≥
             10 cm in length are eligible.

          -  Diagnosis of occlusive thrombus in the graft or artery by arteriography after Informed
             Consent is obtained.

          -  Ability to traverse the thrombus with a guidewire.

          -  Signed informed consent prior to study entry.

        Exclusion Criteria:

          -  Clinical evidence of significant disease that may interfere with the patient
             successfully completing the trial.

          -  Women who are pregnant or lactating, or first 10 days post-partum.

          -  Previous hemorrhagic stroke at any time. Thrombotic or embolic stroke or
             cerebrovascular events (including transient ischemic attack (TIA)) within one year.

          -  Intracranial or spinal neuro-surgery, or severe intracranial trauma in the last 3
             months. Major surgery, organ biopsy, or major trauma within the last 10 days. Lumbar
             puncture or non-compressible arterial puncture in the last 10 days. Intra-ocular
             surgery within the last 10 days.

          -  Current bleeding diathesis. Active gastrointestinal or organ bleeding. Minor bleeding
             such as normal menses, cystitis, or minor hemorrhoidal bleeding are not exclusions.

          -  Uncontrolled arterial hypertension, defined as a systolic blood pressure &gt; 180 mmHg or
             diastolic blood pressure &gt; 110 mmHg.

          -  Known intracranial neoplasm, aneurysm, or arterio-venous malformation.

          -  Platelet count &lt; 75 x 10e9/L.

          -  Occlusion of a graft within 6 months of placement.

          -  Medically unable to tolerate an open vascular procedure.

          -  Known prothrombotic condition.

          -  Hemoglobin &lt;10.0 g/dL

          -  Impaired renal function or renal disease that constitutes a contraindication to
             contrast angiography, including creatinine &gt; 2.0 mg/dL or subjects on renal dialysis.

          -  Treatment with a glycoprotein IIb/IIIa class of platelet inhibitor within the past 5
             days, for example, abciximab (ReoPro®), eptifibatide (Integrilin®) or tirofiban
             (Aggrastat®).

          -  Treatment with warfarin (Coumadin®) and with an INR of &gt;1.7 (elevated INR at screening
             may be corrected prior to study enrollment.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony J Comerota, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jobst Vascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jobst Vascular Institute</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thrombolytic</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>acute peripheral arterial occlusion</keyword>
  <keyword>peripheral vascular disease</keyword>
  <keyword>thrombosis</keyword>
  <keyword>endovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrinolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

